12

February 12, 2019
Published by admin_auro at February 12, 2019
Categories

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA PCGEM1 (Prostate-specific transcript 1)  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and ageing, via down-regulation of its target gene, 12/February/2019, 11.14 pm

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and […]
Do you like it?0
Read more
February 12, 2019
Published by admin_auro at February 12, 2019
Categories

Combinatorial therapy for cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells via up-regulation of its target gene, 12/February/2018, 10.31 pm

Introduction: What they say: A study from the Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts, USA, Department of Biology, Massachusetts Institute of Technology, […]
Do you like it?0
Read more
February 12, 2019
Published by admin_auro at February 12, 2019
Categories

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA HEIH  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 10.21 pm

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
Do you like it?0
Read more
February 12, 2019
Published by admin_auro at February 12, 2019
Categories

Natural product-derived Combination therapy for Squamous cell carcinoma of head and neck (HNSCC): A therapeutic mix encompassing  a therapeutic mix encompassing Metformin and Navitoclax/ABT-263   inhibits BMI1 and AP-1 expression, overcomes chemotherapeutic resistance, promotes chemosensitivity, suppresses cancer stem cells in HNSCC, and inhibits lymph node metastasis, via down-regulation of its target genes, 12/February/2017, 10.13 pm

Introduction: What they say: A study from the Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, Jonsson Comprehensive Cancer Center and Broad Stem Cell Research […]
Do you like it?0
Read more
12
Next page